- Benchmark ASINB0H1L72MRX
- MarketplaceUS
- Category ID7792528011
- Analyzed Products
- Keywordskin care
- Price Range-
- Minimum Net Profit Margin10.00%
- MOQ100
- Est. Purchasing CostNo price data
- Data Date2026-07-30
- Your Budget (for new listing) (CNY)¥500,000.00
Report summary from Keble AI Agent: Listing
结论很明确：这个市场不值得进入，已经是品牌主导、强功效和高试错成本的红海。 新品牌总数只有3个，不满足“新品牌大规模涌入”的过饱和警报，但新品成功并不轻松：新品成功率53.33%，失败率42.86%，而且近期新上架里失败占比并不低，说明竞争正在加剧，不是越来越好做。
Recommended Products Features Direction
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
New Brands
VS
Old Brands
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
New Brands
Old Brands
#Budget Requirement
Listing结论很直接：这个市场能进，但只适合有品牌力的大品牌；对小企业来说不值得进，因为竞争已经很拥挤，且新品牌里已经出现明显的失败信号。 你的50万人民币预算可以覆盖少数单品的早期起步，但不够支撑长期研发、品牌和认证投入；如果按这个赛道当前打法去做，没有差异化基本就是烧钱。
Early sourcing + logistics + marketing budget (USD)N/AExplains the budgetWith all these investments, who has profitable new releases
How many new listings are released by old brands?53.33%New listing success rate (old brands):62.50%New listing success rate (new brands):42.86%Which new brands have these successful new listings?Which old brands have these successful new listings?Other major expensesR&DAlternatives- 平价屏障修护精华：以神经酰胺、泛醇（B5）、胆固醇为核心的基础修护型精华/乳液；通常比PDRN、复合肽类产品更便宜，药妆/大众品牌选择多，适合把需求从“高阶抗老+焕亮”降级为“保湿+修护”。
- 积雪草舒缓精华/安瓶：主打泛红、刺激感、脆弱期维稳，价格通常低于含PDRN与多肽的叠加型精华；对敏感、换季、刷酸后人群更容易上手，替代的是“舒缓与稳定肤感”这一核心诉求。
- 透明质酸补水精华：如果用户只是想要“快速补水、看起来更饱满”，单一玻尿酸精华往往更便宜、品牌选择更多、使用门槛更低；它不能完全替代抗老功效，但能替代一部分“水润、光泽、轻薄吸收”的体验。
- 烟酰胺提亮精华：以较低成本满足肤色不匀、暗沉、细腻度提升的诉求；比含PDRN/高端复合成分的产品更易购买，且通常可在大众护肤线中找到，适合作为“先做提亮再升级”的替代路径。
- 含胜肽的基础抗老乳液/精华：如果用户主要想要“紧致、细纹管理、日常抗老”，更基础的多肽产品通常比复合PDRN科技线更便宜，且日常搭配简单；属于更低预算的中间方案。
- 片状面膜/涂抹式补水面膜：当用户只是想快速获得‘水润、发光、肤感变好’而非长期修护时，面膜的单次成本低、使用直观、购买方便；适合短期替代高价精华的“即时状态改善”需求。
- 温和型修护面霜：若用户不想再叠加一支高价精华，可以直接用一款保湿修护面霜来覆盖补水、锁水、舒缓三类需求；从步骤和预算上都更省心，尤其适合极简护肤人群。
Alternative solutions may pose a risk to your investment in certain markets.
#Brands Investment Analysis
Listing这个市场不适合进入。虽然有少数高利润爆款，但整体已经明显偏向品牌驱动和价格竞争，低风险机会不足；对新品牌来说，能赚钱的窗口很窄。
从数据看，市场并没有“低价乱战到全线亏损”，因为可识别的产品里盈利比例还有71.67%，而新品牌新品盈利率也有53.33%。但这不代表好进：新品牌新品里只有BIODANCE在撑场，BIODANCE 3个可判断新品里2个盈利、1个失利；旧品牌新品盈利率更高，达到62.50%，说明真正能吃到红利的是有资源的成熟品牌。更关键的是，利润高的样本都不是“轻松起盘”的类型：BIODANCE的B0FKSM8L9H售价$21.65，月销5000、月营收$108,250，早期投入$13,403.73，其中广告$2,999.76；B0H1L72MRX售价$21.18，月销3000、月营收$63,540，利润率28.01%，近月利润$35,906.53。对照用户预算500,000 CNY，买得起一条线，但这类成功并不是靠低预算能复制，且BIODANCE还出现了两个新品父体失败（B0H4FKCZN6、B0FPBYW22N），说明新品牌试错成本并不低。
真正值得复制的只有两个样本：一个是成熟品牌medicube的B0DBF65JYY，另一个是新品牌BIODANCE的B0FKT34H9W。 medicube的B0DBF65JYY卖$18.76，月销60,000，月营收$1,125,600，评论19,015，利润率32.48%；B0DCJ7952P卖$18.76，月销10,000，月营收$187,600，评论4,037，利润率28.98%。这些是大品牌打法：品牌力、规模、评论壁垒都很强，不是小商家可直接照搬。小商家唯一可参考的是BIODANCE的B0FKT34H9W：售价$21.08，评论259，利润率32.54%，月销1,000，月营收$21,080；它符合你要的“真小商家成功”标准，但它也不是低门槛模板，而是靠清晰功能点和白帽推广打出来的。要复制的话，只能学它的单点卖法：围绕“提亮/淡斑/修护”做单一核心诉求，控制体积和运费，保持$20-$22价格带，做轻容量、强功效叙事、白帽投放；不要学失败样本那种空泛扩品和父体先行试错。结论很直接：大品牌可以打，但要高投入；小商家没有足够研发/品牌/推广预算就别进，这个市场不值得现在入场。
New products with Highest revenueMost investment in new productsLeast investment in new productsBIODANCE
Recent Monthly Revenue (USD):$108,250.00(5000pcs/month)B0FKSM8L9H (4.5/5 (1448 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableRecent Monthly Revenue (USD):$63,540.00(3000pcs/month)B0H1L72MRX (4.4/5 (186 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitable
Recent Monthly Revenue (USD):$21,080.00(1000pcs/month)B0FKT34H9W (4.4/5 (259 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableOld brand with the most profitable new productsmedicube
Recent Monthly Revenue (USD):$1,125,600.00(60000pcs/month)B0DBF65JYY (4.7/5 (19015 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitable
Recent Monthly Revenue (USD):$187,600.00(10000pcs/month)B0DCJ7952P (4.7/5 (4037 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitableRecent Monthly Revenue (USD):$150,080.00(8000pcs/month)B0DVSNQ37F (4.6/5 (2935 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitableLeast profitable new productscelimax
Recent Monthly Revenue (USD):-(-)B0HBW3N3S9Brand is a new entry in this marketNew ReleaseInsufficient Sales to Meet MOQUnderperformingNot enough sales volume to meet 100 MOQ#Differentiations
Unique productsCommon productsDifferentiation:- 粉色渐变泡沫瓶身，外观最醒目，适合吸引点击
- |
- 微泡泡起泡精华，形态和常规滴管精华差异大
- |
- 主打30秒晨间妆前打底，使用场景很明确
- |
- 适合想要快速补水、玻璃肌光泽的人群
B0H1L72MRX (4.4/5 (186 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableSales & BSR
Differentiation:- 淡米色瓶身配金色背景，修护抗老视觉很鲜明
- |
- 视黄醇+视黄醛+微针护理概念，功能差异强
- |
- 30ml滴管小瓶，和普通保湿精华区分明显
- |
- 更吸引进阶抗老、想改善细纹紧致度的用户
B0FDTZ8Y5Q (4.3/5 (972 Reviews))Brand is an old entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableSales & BSR
#Net Profit Margins: All vs New
Listing这个市场现在不适合新卖家进入，结论很直接：不是机会市场，而是被大品牌和品牌力主导的高强度竞争市场。 新品里看起来能赚钱的，几乎都不是普通小卖家能复制的模式：要么是老牌大品牌的新品，要么是新品牌里少数靠强差异化和前期投入打出来的案例；而近期越新的产品，越多落在未盈利或暂未跑通的状态，说明竞争正在加剧，不是在变松。
Profitability difficultyPotential high net profit marginAll products distribution on different profit levels
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%otherNew products distribution on different profit levels
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%other#Top Products by Net Profit Margin
Top 20 Profitable Products
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
B0DBF65JYYmedicube2024-10-04Yes$18.7660000pcs$1125600.032.48%$365594.88B0CLLV2T1PANUA2023-10-23Yes$21.3940000pcs$855600.029.9%$255824.4
B072K1LNNYSeoulCeuticals2017-06-06Yes$19.3410000pcs$193400.033.46%$64711.64B0C2TQ24VYVT COSMETICS2023-06-17Yes$23.378000pcs$186960.034.17%$63884.24
B086Z6T13DNaturium2020-04-10Yes$19.049000pcs$171360.031.77%$54441.08B0DCJ7952Pmedicube2024-08-08Yes$18.7610000pcs$187600.028.98%$54366.48
B07P5TMHD9Eclat Skincare2019-06-20Yes$16.6610000pcs$166600.030.12%$50179.92B0DVSNQ37Fmedicube2025-02-03Yes$18.768000pcs$150080.031.15%$46749.92B07K3261ZDCeraVe2018-11-01Yes$17.278000pcs$138160.031.58%$43630.93
B0D137TMRBmedicube2024-04-07Yes$19.866000pcs$119160.032.03%$38166.95B09DLFCB69Beauty of Joseon2021-08-25Yes$15.579000pcs$140130.027.13%$38017.27B06Y15D1LHSKIN10042017-04-03Yes$14.9110000pcs$149100.025.32%$37752.12B0FKSM8L9HBIODANCE2025-08-01Yes$21.655000pcs$108250.033.17%$35906.53B0G29RKZ1Hmedicube2025-11-14Yes$17.287000pcs$120960.026.46%$32006.02B091238V7NAXIS-Y2021-10-08Yes$14.798000pcs$118320.025.92%$30668.55
B086YZRHH7Naturium2020-04-10Yes$19.185000pcs$95900.029.43%$28223.37B0GV2J43Q9SKIN10042026-03-27Yes$22.064000pcs$88240.031.73%$27998.56B0F8LBX37XBeauty of Joseon2025-05-14Yes$15.456000pcs$92700.026.2%$24287.4B0DQCLFJCBmedicube2024-12-13Yes$21.173000pcs$63510.033.51%$21282.21B0DZFWBTQBBeauty of Joseon2023-05-09Yes$27.292000pcs$54580.037.98%$20729.49Top 20 Profitable New Products
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
B0FKSM8L9HBIODANCE2025-08-01Yes$21.655000pcs$108250.033.17%$35906.53B0G29RKZ1Hmedicube2025-11-14Yes$17.287000pcs$120960.026.46%$32006.02B0GV2J43Q9SKIN10042026-03-27Yes$22.064000pcs$88240.031.73%$27998.56B0H1L72MRXBIODANCE2026-05-13Yes$21.183000pcs$63540.028.01%$17797.56
B0GQ9PPV61SKIN10042026-02-26Yes$16.73000pcs$50100.025.16%$12605.16B0FKT34H9WBIODANCE2025-08-01Yes$21.081000pcs$21080.032.54%$6859.44B0FDTZ8Y5QSKIN10042025-11-06Yes$13.721000pcs$13720.023.49%$3222.83B0FDXXJT66SKIN10042025-08-13Yes$12.35700pcs$8645.020.41%$1764.45#New Product Success Rates
Listing这个市场不适合进入，结论很明确：老品牌和新品牌都在打高强度价格与功能战，新品成功率虽不低，但失败也很集中，已经接近红海。 你手上有 50万人民币，表面上够做单品启动，但这类市场真正赢的不是“能不能上架”，而是能不能长期砸出品牌力和差异化；按现有数据，普通中小卖家直接切入风险很高。
从成功结构看，新品盈利率是 53.33%，但新品亏损率也有 42.86%，这不是轻松可进的增长市场，而是“做对了能赢、做错了就死”的高压市场。更关键的是，成功几乎被少数品牌吃掉：新品牌里盈利新品几乎只集中在 BIODANCE，亏损也主要集中在 BIODANCE 和 celimax；老品牌里则是 SKIN1004 和 medicube 扛起了大多数成功。样本里的典型赢家不是低价杂牌，而是 B0H1L72MRX（BIODANCE，6.354万美元/月）、B0FKSM8L9H（BIODANCE，10.825万美元/月）、B0G29RKZ1H（medicube，12.096万美元/月）、B0GV2J43Q9（SKIN1004，8.824万美元/月），它们共同特点是：老产品体系延伸、明确功效点、品牌力强，而且有额外研发/包装/营销投入，不是单靠基础铺货就能复制。
New products success rate.
What is the ratio of profitable products
Profitable (Unidentifiable released date)Profitable (Old product)Profitable (New product)Profitable (New product on old listing)New products but non profitableProfitable new products divide by brands
What is the ratio of different brands owning all profitable new products
medicubeSKIN1004BIODANCENonprofitable new products divide by brands
What is the ratio of different brands owning all nonprofitable new products
medicubeSKIN1004BIODANCEcelimax#Success Rate by Entry Time
Listing这个市场不值得进入，已经接近/进入过热竞争区。 近期香港新品牌真正成功很少，而且成功高度集中在 BIODANCE、SKIN1004、medicube 这类已经有品牌力的玩家；对新进入者来说，胜率不够稳，资金也不只是买货和投放，后续还会吃掉研发、品牌和认证成本。
How many products released each year
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
How many products released each month
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
#Net Profit Margins by Entry Time
Different profit ratios of products released in year
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2022 0 0 0 0 0 0 0 0 2023 0 0 0 0 0 0 0 0 2024 0 0 0 0 0 0 0 0 2025 0 0 0 0 3 2 0 2 2026 0 0 0 0 2 1 0 5 ≥ 10% Profitable< 10% UnprofitableUnidentifiableDifferent profit ratios of products released in month
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2025/7 0 0 0 0 0 0 0 0 2025/8 0 0 0 0 1 2 0 0 2025/9 0 0 0 0 0 0 0 2 2025/10 0 0 0 0 0 0 0 0 2025/11 0 0 0 0 2 0 0 0 2025/12 0 0 0 0 0 0 0 0 2026/1 0 0 0 0 0 0 0 0 2026/2 0 0 0 0 1 0 0 1 2026/3 0 0 0 0 0 1 0 0 2026/4 0 0 0 0 0 0 0 2 2026/5 0 0 0 0 1 0 0 0 2026/6 0 0 0 0 0 0 0 1 ≥ 10% Profitable< 10% UnprofitableUnidentifiable#Case Study
Success Cases
Tree of LifeB00WRIRMOA (4.4/5 (143196 Reviews))Tree of Life Hyaluronic Acid Serum for Face - Brightening and Hydrating Face Oil for Dark Spots and Fine Lines - Suitable for Sensitive Skin - Dermatologist Tested Skin Care - 1 Fl Oz
This listing is deemed profitablePrice (USD)$9.73Released TypeOld Release (2016-10-20)Brand is an old entry in this marketSize and Weight10.6 x 3.5 x 3.4 cm, 68.00gProfitable Factors
Established brand with longevityBased on old ASINLow pricing strategyDesign & Appearance
普通透明精华瓶配滴管，绿色包装无明显差异化外观Key Buying Motive
主打基础型透明质酸补水保湿，定位清晰且入门门槛低Target Customers
预算敏感、希望以低价购买基础补水抗初老精华的消费者Early Investment
Investment
Monthly Revenue (Recent) (USD)$9,730.001000 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight11.26% / 13.95%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight7.86% / 10.54%Peak / Non PeakSales & BSR Performance
SeoulCeuticalsB072K1LNNY (4.3/5 (27757 Reviews))SeoulCeuticals Korean Skin Care 20% Vitamin C Serum for Face + CE Ferulic
This listing is deemed profitablePrice (USD)$19.34Released TypeOld Release (2017-06-06)Brand is an old entry in this marketSize and Weight10.3 x 3.4 x 3.4 cm, 71.00gProfitable Factors
Established brand with longevityBased on old ASINDesign & Appearance
橙色外包装与滴管瓶组合，视觉上更偏“高浓度精华”定位, 标准滴管精华包装，非私模结构, 偏大字突出20%维C与CE Ferulic卖点，属于成熟公模市场外观Key Buying Motive
主打20%高浓度维C，并强调接近更昂贵CE Ferulic配方Target Customers
更适合想用较低价格替代高价CE Ferulic、同时关注淡斑提亮和抗老的用户Early Investment
Investment
Monthly Revenue (Recent) (USD)$193,400.0010000 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight32.11% / 33.46%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight30.32% / 31.67%Peak / Non PeakSales & BSR Performance
Loading samples... 17%